Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

tify opportunities to block these mechanisms in order to delay tumor progression."

The abstract can be found at the following link:

http://cancerres.aacrjournals.org/content/71/17/5838.abstract

About Custirsen

Custirsen is the only compound currently in development designed to inhibit the production of clusterin, a protein commonly over-produced in cancer cells, and one cause of treatment resistance. Unlike opioids or agents that target the androgen receptor, custirsen is mechanistically unique in its ability to impact pain responses via the regulation of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity.  This is a potential attribute that could contribute to custirsen's clinical benefit in combination with numerous anti-cancer treatments.

Custirsen has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

More information is available at www.OncoGenex.com and www.tevapharm.com/research.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase III clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase III development of custi
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)... New York, NY (PRWEB) June 02, 2015 ... informative views on health care, Jack Uldrich has ... pharmaceutical firm in New York today. He will ... , Uldrich has delivered presentations to ... American Academies of Audiology and Neurology, Alcetel-Lucent/Verizon Forum ...
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, 2015 ... data from the Phase 3 multicenter study SAR3007, ... (PFS) with trabectedin (YONDELIS ® ) compared to ... leiomyosarcoma (LMS) previously treated with an anthracycline and ... the largest randomized Phase 3 study ever conducted ...
Breaking Biology Technology:R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... - Dr. Liew awarded Malaysia,s Darjah Yang Mulia ... - GeneNews Limited (TSX: GEN),a company focused on ... of diseases and personalized health management, today,announced that ... Liew,was awarded the Darjah Yang Mulia Pangkuan Negeri ...
... Imprint to Yield a Strong and ... Highly Specific Immune Response, ... ILNS) a biopharmaceutical company focused on,development of disease-modifying therapeutic agents ... announced today,that Dr. Rachel Eren, Vice President Research, will present ...
... Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced that ... than,35% over the first quarter of 2007 exceeding $1,872,000 ... same period in the previous year. Revenues for ... only,$24,374 in the first half of 2006. These significant ...
Cached Biology Technology:GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... for Secure and Resilient Maritime Commerce (CSR) at Stevens Institute ... Stevens was named by the US Department of Homeland Security ... and was selected to lead a national research effort to ... partner with the DHS and serve as an important team ...
... Ind. - One of the most common house ant species ... smallest spaces in a forest, but the ants have found ... Grzegorz Buczkowski, a Purdue University research assistant professor of ... more complex as they move from forest to city and ...
... their wide-view neurostimulator concept a bionic eye that ... technology. The prototype bionic eye, developed by ... and unveiled today at the BVA consortium,s official launch ... of life for patients suffering from degenerative vision loss ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Bionic Vision Australia puts bionic eye in sight 2
... d1-174 GenBank Accession Number : NM_006225 ... tagged fusion protein corresponding to full length ... pH 7.4, 0.15M NaCl, 0.05% sodium azide ... Quality Assurance: routinely evaluated by immunoblot on ...
Request Info...
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: